416 related articles for article (PubMed ID: 23322995)
21. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
Colman RJ; Rubin DT
J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
[TBL] [Abstract][Full Text] [Related]
22. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
23. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
24. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
Patil SA; Rustgi A; Langenberg P; Cross RK
Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
[TBL] [Abstract][Full Text] [Related]
26. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
27. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
[TBL] [Abstract][Full Text] [Related]
28. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
29. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
[TBL] [Abstract][Full Text] [Related]
30. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India.
Sahu P; Vuyyuru SK; Kante B; Agarwal A; Sharma R; Das P; Panwar R; Jain S; Bopanna S; Makharia G; Kedia S; Ahuja V
Indian J Gastroenterol; 2020 Aug; 39(4):388-397. PubMed ID: 32880844
[TBL] [Abstract][Full Text] [Related]
31. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
Bodini G; Demarzo MG; Saracco M; Coppo C; De Maria C; Baldissarro I; Savarino E; Savarino V; Giannini EG
Scand J Gastroenterol; 2019 Oct; 54(10):1220-1225. PubMed ID: 31553630
[No Abstract] [Full Text] [Related]
32. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
[TBL] [Abstract][Full Text] [Related]
33. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
34. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.
Lew D; Yoon SM; Yan X; Robbins L; Haritunians T; Liu Z; Li D; McGovern DP
World J Gastroenterol; 2017 Oct; 23(40):7265-7273. PubMed ID: 29142473
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
37. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
[TBL] [Abstract][Full Text] [Related]
38. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
Thomas PWA; Römkens TEH; West RL; Russel MGVM; Jansen JM; van Lint JA; Jessurun NT; Hoentjen F
United European Gastroenterol J; 2021 Oct; 9(8):919-928. PubMed ID: 34077634
[TBL] [Abstract][Full Text] [Related]
39. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
[TBL] [Abstract][Full Text] [Related]
40. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Dai C; Wang YN; Tian WN; Huang YH; Jiang M
Int Immunopharmacol; 2022 Nov; 112():109269. PubMed ID: 36182873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]